B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Balchem Co. (NASDAQ:BCPC) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 14,736 shares of the basic materials company’s stock, valued at approximately $1,687,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. CI Investments Inc. increased its position in shares of Balchem by 444.0% during the fourth quarter. CI Investments Inc. now owns 272 shares of the basic materials company’s stock valued at $31,000 after buying an additional 222 shares during the period. Acadian Asset Management LLC bought a new stake in Balchem during the third quarter worth about $56,000. Veriti Management LLC bought a new stake in Balchem during the fourth quarter worth about $120,000. 6 Meridian bought a new stake in Balchem during the fourth quarter worth about $205,000. Finally, Bailard Inc. bought a new position in shares of Balchem in the fourth quarter worth approximately $217,000. Institutional investors own 85.01% of the company’s stock.
Shares of BCPC stock opened at $120.87 on Thursday. Balchem Co. has a 12 month low of $79.75 and a 12 month high of $132.50. The stock has a market cap of $3.92 billion, a P/E ratio of 47.40 and a beta of 0.54. The company has a current ratio of 3.95, a quick ratio of 2.82 and a debt-to-equity ratio of 0.25. The company has a 50 day simple moving average of $124.20 and a two-hundred day simple moving average of $112.84.
Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Thursday, February 18th. The basic materials company reported $0.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.81 by $0.02. The firm had revenue of $180.70 million during the quarter, compared to analysts’ expectations of $175.33 million. Balchem had a net margin of 12.02% and a return on equity of 14.01%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.88 earnings per share. As a group, equities analysts forecast that Balchem Co. will post 2.88 earnings per share for the current year.
Several research analysts have recently issued reports on BCPC shares. Zacks Investment Research upgraded shares of Balchem from a “strong sell” rating to a “strong-buy” rating and set a $144.00 target price on the stock in a research note on Friday, April 2nd. Stephens upgraded shares of Balchem from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $100.00 to $140.00 in a research note on Monday, March 1st. Finally, HC Wainwright upped their target price on shares of Balchem from $126.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, March 1st.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Further Reading: What causes a recession?
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.